(Adnkronos) - "L’alleanza tra due aziende farmaceutiche come Astrazeneca e Daiichi Sankyo può accelerare l’innovazione e l’accesso a questi farmaci davvero straordinari per la cura del tumore al seno metastatico” ha spiegato Alessandra Dorigo, head of oncology di AstraZeneca, in occasione della presentazione della campagna di sensibilizzazione di Daiichi Sankyo e AstraZeneca intitolata "In Seno al Futuro" dedicata al tumore al seno metastatico: “Forte ritardo dell’arrivo dei farmaci in ospedale, l’Ocse pone l’Italia al decimo posto tra i Paesi europei”.
Category
🗞
NewsTranscript
00:00I would start by saying that science is a collective challenge, where collaboration is fundamental.
00:11The team play is fundamental, where we have to put experience, competence and human capital in common.
00:21In addition, I think that the actors present at today's table share a great sense of responsibility
00:28to try to challenge the status quo of the diagnostic-therapeutic path of people with metastatic breast cancer in Italy,
00:38and therefore where each of us can really contribute to change things.
00:44I must say, the other very nice thing is to see not only two patient associations
00:51that work with women affected by metastatic breast cancer together,
00:57but also two pharmaceutical companies such as AstraZeneca and ICSAN,
01:01which were key in setting up this alliance,
01:06an alliance that is based on the co-development and co-commercialization of this revolution in metastatic breast cancer,
01:14and therefore, once again, to go beyond what was perhaps a world where pharmaceutical companies lived a sense of competition with each other,
01:23but to try to understand the excellences that each of them can bring to the table
01:29to try to accelerate innovation, but above all to accelerate access to these truly revolutionary drugs.